Last reviewed · How we verify

Methylene blue (1%)

University Hospital, Strasbourg, France · FDA-approved active Small molecule

Methylene blue (1%) is a Redox agent; monoamine oxidase inhibitor Small molecule drug developed by University Hospital, Strasbourg, France. It is currently FDA-approved for Methemoglobinemia (acute treatment), Ifosfamide-induced encephalopathy (off-label), Cognitive impairment and depression (investigational).

Methylene blue acts as a redox agent and monoamine oxidase inhibitor, helping to restore cellular electron transport and reduce oxidative stress.

Methylene blue acts as a redox agent and monoamine oxidase inhibitor, helping to restore cellular electron transport and reduce oxidative stress. Used for Methemoglobinemia (acute treatment), Ifosfamide-induced encephalopathy (off-label), Urinary tract infections (antiseptic).

At a glance

Generic nameMethylene blue (1%)
SponsorUniversity Hospital, Strasbourg, France
Drug classRedox agent; monoamine oxidase inhibitor
TargetMitochondrial electron transport chain; monoamine oxidase; methemoglobin reductase
ModalitySmall molecule
Therapeutic areaMultiple (Toxicology, Psychiatry, Infectious Disease, Hematology)
PhaseFDA-approved

Mechanism of action

Methylene blue functions as a reversible oxidation-reduction (redox) compound that can accept and donate electrons, facilitating mitochondrial electron transport and ATP production. It also inhibits monoamine oxidase and has antimicrobial properties. Additionally, it can reduce methemoglobin back to hemoglobin, making it useful in treating methemoglobinemia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Methylene blue (1%)

What is Methylene blue (1%)?

Methylene blue (1%) is a Redox agent; monoamine oxidase inhibitor drug developed by University Hospital, Strasbourg, France, indicated for Methemoglobinemia (acute treatment), Ifosfamide-induced encephalopathy (off-label), Cognitive impairment and depression (investigational).

How does Methylene blue (1%) work?

Methylene blue acts as a redox agent and monoamine oxidase inhibitor, helping to restore cellular electron transport and reduce oxidative stress.

What is Methylene blue (1%) used for?

Methylene blue (1%) is indicated for Methemoglobinemia (acute treatment), Ifosfamide-induced encephalopathy (off-label), Cognitive impairment and depression (investigational), Urinary tract infections (antimicrobial use).

Who makes Methylene blue (1%)?

Methylene blue (1%) is developed and marketed by University Hospital, Strasbourg, France (see full University Hospital, Strasbourg, France pipeline at /company/university-hospital-strasbourg-france).

What drug class is Methylene blue (1%) in?

Methylene blue (1%) belongs to the Redox agent; monoamine oxidase inhibitor class. See all Redox agent; monoamine oxidase inhibitor drugs at /class/redox-agent-monoamine-oxidase-inhibitor.

What development phase is Methylene blue (1%) in?

Methylene blue (1%) is FDA-approved (marketed).

What are the side effects of Methylene blue (1%)?

Common side effects of Methylene blue (1%) include Blue discoloration of urine and skin, Nausea and gastrointestinal upset, Headache, Dizziness, Serotonin syndrome (rare, with serotonergic agents).

What does Methylene blue (1%) target?

Methylene blue (1%) targets Mitochondrial electron transport chain; monoamine oxidase; methemoglobin reductase and is a Redox agent; monoamine oxidase inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing